Provided by Tiger Trade Technology Pte. Ltd.

HANSOH PHARMA

31.540
-0.640-1.99%
Volume:9.96M
Turnover:314.16M
Market Cap:191.26B
PE:28.92
High:32.860
Open:32.380
Low:31.180
Close:32.180
52wk High:43.587
52wk Low:27.658
Shares:6.06B
HK Float Shares:6.06B
Volume Ratio:1.25
T/O Rate:0.16%
Dividend:0.50
Dividend Rate:1.57%
EPS(LYR):1.091
ROE:19.40%
ROA:9.08%
PB:4.32
PE(LYR):28.92
PS:10.26

Loading ...

Hansoh Pharmaceutical Group Stock Slides 1.9% in Hong Kong

Dow Jones
·
Sep 11

Hansoh Pharma Says NMPA Grants Priority Review for HS-20093 in Small Cell Lung Cancer

Reuters
·
Sep 11

Hansoh Pharmaceutical - Risvutatug Rezetecan for Injection Included in Nmpa Priority Review for Small Cell Lung Cancer

THOMSON REUTERS
·
Sep 11

Movement Alert|HANSOH PHARMA Falls 3.06% in Regular Trading, Post-Earnings Rally Continues to Retrace Amid Sector Weakness

Market Focus
·
Sep 11

Hansoh Pharmaceutical Group Stock Falls 4.2% in Hong Kong

Dow Jones
·
Sep 10

Movement Alert|HANSOH PHARMA Falls 3.22% in Regular Trading, Pharmaceutical Sector Under Broad Pressure as Post-Earnings Rally Continues to Retrace

Market Focus
·
Sep 10

Hansoh Pharmaceutical Group Stock Falls 3.5% in Hong Kong

Dow Jones
·
Sep 09

UBS: Mixed First-Half Results for Chinese Pharma Stocks, Names Simcere as Top Pick

Stock News
·
Sep 09

Movement Alert|HANSOH PHARMA Falls 3.1% in Regular Trading, Broad Pharma Sector Selloff Drags Down Stock

Market Focus
·
Sep 09

CLSA Highlights Return of Stock-Specific Drivers in China's Innovative Drug Sector, Sees Macro Swings as Entry Points

Stock News
·
Sep 09

Hansoh Pharma Says China NMPA Accepts BLA for HS-20093 in Small Cell Lung Cancer

Reuters
·
Sep 07

One-Day Surge, Three-Day Slump: Can Hansoh Pharma's Shares Climb Back to HK$40?

Stock News
·
Sep 02

HANSOH PHARMA's Investigational ADC for Small Cell Lung Cancer Wins NMPA Filing Acceptance

Stock News
·
Sep 02

Hansoh Pharma Says China NMPA Accepts HS-20093 BLA for Small Cell Lung Cancer

Reuters
·
Sep 02

Hansoh Pharmaceutical Group Stock Climbs 2.2% in Hong Kong

Dow Jones
·
Sep 02

Hansoh Pharmaceutical Says NMPA Accepts Biologics License Application of HS-20093

Reuters
·
Sep 02

CLSA Lifts Hansoh Pharma Target Price to HK$43.70, Reaffirms Outperform Rating

Deep News
·
Sep 01

Movement Alert|HANSOH PHARMA Declines 3.28% in Regular Trading, Post-Earnings Profit-Taking Extends Amid Pharma Sector Weakness

Market Focus
·
Sep 01

JPMorgan Reaffirms 'Overweight' on Hansoh Pharma, Lifts Target Price to HK$50

Stock News
·
Aug 31

Hansoh Pharmaceutical Group Stock Sheds 3.8% in Hong Kong

Dow Jones
·
Aug 31